NCCN Guidelines for Thyroid Carcinoma V 1.
2022 – 01/26/2022
Guideline Page
and Request
ANAP-A 2 of 3
Comment to consider the inclusion of
doxorubicin/cisplatin as a systemic therapy option
for metastatic anaplastic thyroid carcinoma, based
on the updated ATA Guidelines for management
of anaplastic thyroid carcinoma.
ANAP-A 2 of 3
Comment to reassess the continued inclusion of
paclitaxel/carboplatin as a systemic therapy option
for metastatic anaplastic thyroid carcinoma, based
on the updated ATA Guidelines for management
of anaplastic thyroid carcinoma.
ANAP-A 2 of 3
Comment to reassess the continued inclusion of
docetaxel/doxorubicin as a systemic therapy
option for metastatic anaplastic thyroid carcinoma,
based on the updated ATA Guidelines for
management of anaplastic thyroid carcinoma.
Institution Vote
Panel Discussion/References ABSEN
YES NO ABSTAIN
T
Based on the review of the data, the panel
consensus was to include doxorubicin/cisplatin
as a systemic therapy option for metastatic
anaplastic thyroid carcinoma. This is a category
2A, useful in certain circumstances regimen.
19 0 6 9
Bible KC, Kebebew E, Brierley J, et al. 2021
american thyroid association guidelines for
management of patients with anaplastic thyroid
cancer. Thyroid 2021;31:337-386.
Based on the review of the data, the panel
consensus was that paclitaxel/carboplatin has
limited clinical use for the treatment of metastatic
anaplastic thyroid carcinoma, and the category
was changed from a category 2A (other
recommended) regimen to a category 2B, other
recommended regimen. 8 4 14 8
Bible KC, Kebebew E, Brierley J, et al. 2021
american thyroid association guidelines for
management of patients with anaplastic thyroid
cancer. Thyroid 2021;31:337-386.
Based on the review of the data, the panel
consensus was that docetaxel/doxorubicin has
limited clinical use for the treatment of metastatic
anaplastic thyroid carcinoma, and the category
7 4 14 9
was changed from a category 2A (other
recommended) regimen to a category 2B, other
recommended regimen.
NCCN Guidelines for Thyroid Carcinoma V 1.2022 – 01/26/2022

Bible KC, Kebebew E, Brierley J, et al. 2021

american thyroid association guidelines for
management of patients with anaplastic thyroid
cancer. Thyroid 2021;31:337-386.